Detection of skeletal adverse events following ICI therapy using FEARS database to describe emerging trends of skeletal adverse events
Latest Information Update: 14 Nov 2019
At a glance
- Drugs Atezolizumab (Primary) ; Durvalumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 14 Nov 2019 New trial record
- 06 Nov 2019 Results presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research